RxDoctor Payments Data

Ana Apoltan, MD

Internal Medicine · Coconut Creek, FLNPI 1952377277

Payments from drug & device makers

$5,575in general payments, 2019–2025

Across 311 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$775
  • Exact Sciences$747
  • Boehringer Ingelheim$736
  • Novo Nordisk$582
  • Amgen$394
  • Lilly USA, LLC$366
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,49599%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,575 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$97,844
Medicare patients
248
Services billed
1,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$121,725
OzempicSemaglutide80$109,536
JanuviaSitagliptin Phosphate40$57,062
EliquisApixaban22$33,256
TradjentaLinagliptin16$23,543
FarxigaDapagliflozin Propanediol16$20,289
MounjaroTirzepatide12$13,383
XareltoRivaroxaban11$9,673
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,472
Olmesartan Medoxomil173$2,492
Rosuvastatin Calcium284$2,197
Atorvastatin Calcium327$2,186
Levothyroxine Sodium184$1,825
SynthroidLevothyroxine Sodium16$1,791
Amlodipine Besylate369$1,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$736$145,26898 claims
Novo NordiskOzempic$582$109,53680 claims
PfizerEliquis$214$33,25622 claims
AstraZenecaFarxiga$77$20,28916 claims
Lilly USA, LLCMounjaro$366$13,38312 claims
Johnson & JohnsonXarelto$50$9,67311 claims
AbbVieSynthroid$141$1,79116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Coconut Creek

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →